Genitourinary Cancers

Promising results were obtained with enzalutamide monotherapy in patients with hormone-naive prostate cancer. Read More ›

Prostate cancer screening with prostate-specific antigen (PSA) tests should focus on men aged 55 to 69 years, the group that is the most likely to benefit from screening. Read More ›

The US Food and Drug Administration (FDA) approved axitinib (Inlyta; Pfizer, Inc.) for the treatment of patients with advanced renal cell carcinoma after failure of 1 prior systemic therapy. This approval was granted on January 27, 2012. For more information about the FDA approval, see http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289439.htm. Read More ›

The US Food and Drug Administration (FDA) approved enzalutamide (Xtandi; Medivation, Inc., Astellas Pharma US, Inc.) for the treatment of patients with metastatic castration-resistant prostate cancer who had previously received docetaxel. Read More ›

Abiraterone acetate is a novel antiandrogen agent that has recently received an expanded indication for treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Read More ›

In March, the National Compre-hensive Cancer Network (NCCN) guidelines for genetic/familial high-risk assessment for breast and ovarian cancers were updated. Read More ›


Two studies presented at the 2012 American Society of Clinical On­cology (ASCO) Annual Meet­ing suggested that abiraterone acetate (AA; Zytiga), an androgen biosynthesis inhibitor,1 has the potential to be used earlier in the course of prostate cancer than its current US Food and Drug Administration (FDA) indication (ie, after failure of chemotherapy in men with metastatic castration-resistant prostate cancer [CRPC]).

Read More ›

The novel agent MDV3100 prolonged survival in men with castration- resistant prostate cancer (CRPC) who progressed on treatment with docetaxel, according to results of the large phase 3 AFFIRM trial reported at the 2012 American Society of Clinical Oncology Genitourinary Cancers Symposium held in San Francisco, California.

Read More ›

Although the increased incidence of bladder cancer (BC) has softened in recent years, proposed to be due in part to smoking cessation strategies, BC remains a significant healthcare problem with high recurrence rates.1,2 Currently, there is inadequate evidence that screening for BC in the asymptomatic population promotes improved overall morbidity or mortality.3 Despite this current state of the science, there is great interest in bettering the gold standard for early diagnosis—cystoscopy, cytology, and imaging—as these are expensive, uncomfortable, and not Read More ›


Page 4 of 6


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: